Literature DB >> 16608892

Metabolic factors associated with benign prostatic hyperplasia.

J Kellogg Parsons1, H Ballentine Carter, Alan W Partin, B Gwen Windham, E Jeffrey Metter, Luigi Ferrucci, Patricia Landis, Elizabeth A Platz.   

Abstract

CONTEXT: Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear. Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth.
OBJECTIVE: The objective of this study was to determine whether obesity, fasting plasma glucose concentration, and diabetes are associated with radiologically determined prostate enlargement, an objective measure of benign prostatic hyperplasia.
DESIGN: This study was a cross-sectional analysis with robust variance estimates to account for multiple measures over time in the same individuals.
SETTING: This prospective cohort study was composed of community volunteers. PATIENTS: Patients studied were 422 adult men enrolled in The Baltimore Longitudinal Study of Aging. MAIN OUTCOME MEASUREMENTS: Total prostate volume as determined by pelvic magnetic resonance imaging was measured.
RESULTS: Among 422 participants, 91 (21.6%) had prostate enlargement (defined as total prostate volume >/= 40 cc) at first visit. Compared with men of normal weight [body mass index (BMI) < 25 kg/m(2)], the age-adjusted odds ratio (OR) for prostate enlargement for overweight men (BMI, 25-29.9 kg/m(2)) was 1.41 (95% CI, 0.84-2.37), for obese men (BMI, 30-34 kg/m(2)) was 1.27 (95% CI, 0.68-2.39), and for severely obese men (BMI >/= 35 kg/m(2)) was 3.52 (95% CI, 1.45-8.56) (P = 0.01). Men with elevated fasting glucose (>110 mg/dl) were more likely to have an enlarged prostate than men with normal fasting glucose (</=110 mg/dl) (OR, 2.98; 95% CI, 1.70-5.23), as were men with a diagnosis of diabetes (OR, 2.25; 95% CI, 1.23-4.11).
CONCLUSIONS: Obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16608892      PMCID: PMC2645661          DOI: 10.1210/jc.2005-2799

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  62 in total

1.  Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.

Authors:  G Theyer; G Kramer; I Assmann; E Sherwood; W Preinfalk; M Marberger; O Zechner; G E Steiner
Journal:  Lab Invest       Date:  1992-01       Impact factor: 5.662

Review 2.  Optimising the medical management of benign prostatic hyperplasia.

Authors:  Michael Marberger; Richard Harkaway; Jean de la Rosette
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096

3.  A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy.

Authors:  P H Chyou; A M Nomura; G N Stemmermann; J H Hankin
Journal:  Prostate       Date:  1993       Impact factor: 4.104

4.  Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study.

Authors:  E A Platz; I Kawachi; E B Rimm; W C Willett; E Giovannucci
Journal:  J Urol       Date:  2000-02       Impact factor: 7.450

5.  Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.

Authors:  J Hammarsten; B Högstedt
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

6.  Urologic diseases in America project: benign prostatic hyperplasia.

Authors:  John T Wei; Elizabeth Calhoun; Steven J Jacobsen
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

7.  Physical activity and benign prostatic hyperplasia.

Authors:  E A Platz; I Kawachi; E B Rimm; G A Colditz; M J Stampfer; W C Willett; E Giovannucci
Journal:  Arch Intern Med       Date:  1998-11-23

8.  Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study.

Authors:  W R Seitter; E Barrett-Connor
Journal:  Am J Epidemiol       Date:  1992-03-01       Impact factor: 4.897

9.  High-risk group for benign prostatic hypertrophy.

Authors:  H Araki; H Watanabe; T Mishina; M Nakao
Journal:  Prostate       Date:  1983       Impact factor: 4.104

10.  Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels.

Authors:  T Soygür; B Küpeli; K Aydos; S Küpeli; N Arikan; Y Z Müftüoğlu
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

View more
  85 in total

1.  Towards the prevention and management of prostatic diseases in Nigeria: a framework.

Authors:  Chukwunonso Ecc Ejike
Journal:  Malays J Med Sci       Date:  2011-07

2.  Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume.

Authors:  Jay H Fowke; Sharon Phillips; Tatsuki Koyama; Susan Byerly; Raoul Concepcion; Saundra S Motley; Peter E Clark
Journal:  BJU Int       Date:  2012-06-22       Impact factor: 5.588

3.  Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.

Authors:  Ajit Vikram; Gopabandhu Jena; Poduri Ramarao
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

4.  A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia.

Authors:  Yasukazu Nakanishi; Hitoshi Masuda; Satoru Kawakami; Mizuaki Sakura; Yasuhisa Fujii; Kazutaka Saito; Fumitaka Koga; Masaya Ito; Junji Yonese; Iwao Fukui; Kazunori Kihara
Journal:  Asian J Androl       Date:  2012-07-09       Impact factor: 3.285

5.  Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients.

Authors:  Xiaobing Qu; Zhichao Huang; Xianqin Meng; Xiangyu Zhang; Lini Dong; Xiaokun Zhao
Journal:  Int Urol Nephrol       Date:  2014-03       Impact factor: 2.370

6.  Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients.

Authors:  Seung Hwan Lee; Cheol Young Oh; Kyung Kgi Park; Mun Su Chung; Se Jeong Yoo; Byung Ha Chung
Journal:  Asian J Androl       Date:  2011-04-18       Impact factor: 3.285

7.  Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older.

Authors:  Mohammad Reza Safarinejad
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

8.  Risk of cancer in a large cohort of U.S. veterans with diabetes.

Authors:  Elizabeth A Atchison; Gloria Gridley; J Daniel Carreon; Michael F Leitzmann; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

9.  Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Zongwei Wang; Mark G Vangel; Chin-Lee Wu; Shahin Tabatabaei; Aria F Olumi
Journal:  J Urol       Date:  2015-04-25       Impact factor: 7.450

10.  NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.

Authors:  David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Robert J Matusik; Ren J Jin; Simon W Hayward
Journal:  Prostate       Date:  2016-05-16       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.